FDA approves Pluvicto for metastatic castration-resistant prostate cancer

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

Clinical Roundup

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

November 08, 2024

Vol.50 No.42

Drugs & Targets

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

Regulatory News

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.

November 01, 2024

Vol.50 No.41

By Claire Marie Porter

Drugs & Targets

FDA approves Scemblix for newly diagnosed CML patients

Scemblix (asciminib) was granted accelerated approval by FDA for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

November 01, 2024

Vol.50 No.41

FDA approves Pluvicto for metastatic castration-resistant prostate cancer

YOU MAY BE INTERESTED IN

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA approves Scemblix for newly diagnosed CML patients

Renew today!

Subscriber content

Login

FDA approves Pluvicto for metastatic castration-resistant prostate cancer

YOU MAY BE INTERESTED IN

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference

FDA approves Scemblix for newly diagnosed CML patients

Login

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment